Cargando…

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

BACKGROUND: Cellular proliferation, driven by cyclin-dependent kinases (CDKs) and their cyclin partners, is deregulated in cancer. Anti-estrogens, such as tamoxifen, antagonise estrogen-induced ERα transactivation of cyclin D1, resulting in reduced CDK4/6 activity, p27(Kip1)-mediated inhibition of C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, N, Bentley, J, Wang, L-Z, Newell, D R, Robson, C N, Shapiro, G I, Curtin, N J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816653/ https://www.ncbi.nlm.nih.gov/pubmed/20010939 http://dx.doi.org/10.1038/sj.bjc.6605479

Ejemplares similares

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer
por: Coley, H M, et al.
Publicado: (2012)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

Recruitment of trimeric proliferating cell nuclear antigen by G1-phase cyclin-dependent kinases following DNA damage with platinum-based antitumour agents
por: He, G, et al.
Publicado: (2013)

Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21
por: He, G, et al.
Publicado: (2006)

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses
por: Dolly, Saoirse O, et al.
Publicado: (2017)

BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation
por: Loriot, Y, et al.
Publicado: (2010)

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
por: Zaremba, T, et al.
Publicado: (2009)

Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment
por: Takagi, K, et al.
Publicado: (2013)

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
por: Peasland, A, et al.
Publicado: (2011)

High cyclin B1 expression is associated with poor survival in breast cancer
por: Aaltonen, K, et al.
Publicado: (2009)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Attenuation of muscle atrophy in a murine model of cachexia by inhibition of the dsRNA-dependent protein kinase
por: Eley, H L, et al.
Publicado: (2007)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
por: Klawitter, J, et al.
Publicado: (2009)

The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer
por: Someya, M, et al.
Publicado: (2011)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response
por: Rajkumar, V, et al.
Publicado: (2015)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo
por: Steele, N, et al.
Publicado: (2009)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
por: Patterson, M J, et al.
Publicado: (2014)

Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase
por: Rumjahn, S M, et al.
Publicado: (2007)

Upregulation of calcium-sensing receptor and mitogen-activated protein kinase signalling in the regulation of growth and differentiation in colon carcinoma
por: Bhagavathula, N, et al.
Publicado: (2005)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
por: Saha, M N, et al.
Publicado: (2014)

Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2
por: Yeung, B H Y, et al.
Publicado: (2008)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome
por: Kumar, S R, et al.
Publicado: (2007)

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013)

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
por: Bartlett, J M S, et al.
Publicado: (2015)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
por: Montagut, C, et al.
Publicado: (2010)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5ue9hv278mk4gou90acrf7i60d